Coadministration of losartan (50 mg single dose) and glecaprevir/pibrentasvir increased the Cmax and AUC of losartan by 2.51-fold and 1.56-fold; Cmax of losartan carboxylic acid increased by 2.18-fold, whereas AUC and Cmin were unchanged. No dose adjustment is required.

No dose adjustment is required when Mavyret is coadministered with losartan. Coadministration of losartan (50 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Cmax and AUC of losartan increased by 2.51-fold and 1.56-fold; Cmax of losartan acid increased by 2.18-fold but there was no change in AUC.

Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and losartan (50 mg single dose) was studied in 12 healthy subjects. Losartan Cmax and AUC increased by 151% and 56%; Cmax of the losartan active carboxylic metabolite increased by 118%, but AUC was similar (14% or less difference). Exposures of glecaprevir and pibrentasvir were similar (23% or less difference). No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with losartan.